. 2014 Apr 15;7(5):2624–2635.

Table 2.

Reports of AIHA associated with PRCA

Case	Age/sex	Treatment of AIHA	Outcome of AIHA	Complication	Treatment of complications	Outcome of the complications	Interval between the onset of AIHA and the onset of PRCA	Cause of PRCA	Treatment of PRCA	Outcome of PRCA	Note	Ref.
1	46/M	ACTH	Improvement	None	None	None	Simultaneous	None	ACTH	Improvement		[1]
1	46/M	Splenectomy	Improvement	None	None	None	Simultaneous	None	Splenectomy	Improvement		[1]
2	58/F	Cortisone	Improvement	None	None	None	-9 M	None	ACTH Cortisone	Improvement		[2]
2	58/F	Splenectomy	Improvement	None	None	None	-9 M	None	Splenectomy	Improvement		[2]
3	15/F	Cortisone	Improvement	None	None	None	8 M	Contrast media?	Cortisone	No improvement		[3]
3	15/F	Splenectomy	Improvement	None	None	None	8 M	Contrast media?	Cortisone	No improvement		[3]
4	63/n.a	Cortisone	Improvement	Lymphoma	Cortisone	Improvement	Simultaneous	None	Cortisone	Improvement	Hypergammaglobulinemia	[4]
4	63/n.a	Nitrogen mustard	Improvement	Lymphoma	Nitrogen mustard	Improvement	Simultaneous	None	Nitrogen mustard	Improvement	Hypergammaglobulinemia	[4]
5	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a	n.a		[5]
6	76/M	PSL 30 mg	Improvement	None	None	None	-1 M and 3 W	None	PSL 30 mg	Improvement		[6]
7	68/M	PSL 30 mg	Improvement	None	None	None	Simultaneous	None	PSL 30 mg	Recurrence after improvement		[6]
7	68/M	PSL 30 mg	Improvement	None	None	None	Simultaneous	None	PSL 30 mg	Death from Tb		[6]
8	51/M	mPSL 60 mg	Improvement	None	None	None	Simultaneous	None	mPSL 60 mg	Improvement		[7]
8	51/M	ACTH	Improvement	None	None	None	Simultaneous	None	ACTH	Improvement		[7]
9	56/F	PSL 60 mg	Improvement	SLE	PSL 60 mg	n.a	7 M	SLE	PSL 100 mg	Improvement		[8]
10	71/M	PSL 60 mg	Improvement	Lymphoma	PSL 60 mg	Improvement	Simultaneous	Lymphoma	PSL 60 mg	Improvement	Polyclonal hypergammaglobulinemia	[9]
		VCR		RA					VCR	Death from pneumonia and subacute hepatitis	Cold agglutinins
		AZP 50 mg							AZP 50 mg
		Anabolic hormone 200 mg every other day							Anabolic hormone 200 mg every other day
11	66/F	COP	Improvement	Lymphoma	COP	Improvement	Simultaneous	Lymphoma	COP	Improvement		[10]
12	67/M	PSL	Improvement	B-CLL	Chlorambucil	Improvement	32 M	None	PSL	Improvement		[11]
12	67/M	Immunoadsorption	Improvement	B-CLL	PSL	Improvement	32 M	None	Immunoadsorption	Improvement		[11]
13	12/M	n.a	n.a	n.a	n.a	n.a	Simultaneous	HPV B19	None	Improvement		[12]
14	1/n.a	n.a	n.a	n.a	n.a	n.a	n.a	None	n.a	n.a		[13]
15	0.5/n.a	n.a	n.a	n.a	n.a	n.a	n.a	None	n.a	n.a		[13]
16	12/n.a	n.a	n.a	n.a	n.a	n.a	n.a	HPV B19	n.a	n.a		[13]
17	58/M	Cortisone	Improvement	None	None	None	-6 y	Thymoma	Cortisone	Improvement		[14]
17	58/M	Cortisone	Improvement	None	None	None	-6 y	Thymoma	Thymectomy	Improvement		[14]
18	33/F	PSL	Improvement	None	None	None	8 Y	HPV B19	PSL	Improvement		[15]
18	33/F	CPA	Improvement	None	None	None	8 Y	HPV B19	PSL	Improvement		[15]
19	41/F	PSL 60 mg	Improvement	HA	n.a	Improvement	Simultaneous	HA	PSL 60 mg	Improvement		[16]
20	61/M	COP	Improvement	Lymphoma	COP	n.a	Simultaneous	Lymphoma	COP	No improvement	Polyclonal hypergammaglobulinemia	[17]
		CPA 50 mg			CPA 50 mg				CPA 50 mg
		PSL 80 mg			PSL 80 mg				PSL 80 mg
		IVIG			IVIG				IVIG
		MACOPB			MACOPB				MACOPB
21	54/F	PSL 60 mg	Improvement	None	None	None	Simultaneous	HPV B19	PSL 60 mg	Improvement	Normal immunoglobulin	[18]
22	52/F	PSL 60 mg	Improvement	Lymphoma	Chemotherapy	Death from leukemic transformation	-6 M	None	PSL 60 mg	Improvement		[19]
23	35/F	PSL 50 mg	Improvement	None	None	None	4 Y	None	PSL	Improvement	Monoclonal gammopathy	[20]
									mPSL
									AZP 100 mg
24	28/F	PSL 1 mg/kg	n.a	SLE	PSL 1 mg/kg	n.a	Simultaneous	None	PSL 1 mg/kg	Improvement	Polyclonal hypergammaglobulinemia	[21]
24	28/F	PSL 1 mg/kg	n.a	SLE	PSL 1 mg/kg	n.a	Simultaneous	None	IVIG	Improvement	Polyclonal hypergammaglobulinemia	[21]
25	62/F	PSL 1 mg/kg	No improvement	Lymphoma	PSL 1 mg/kg	No improvement	Simultaneous	Lymphoma	PSL 1 mg/kg	No improvement		[22]
		IVIG			IVIG				IVIG	Death from sepsis
		CsA			CsA				CsA
		Anti-lymphocyte antibodies			Anti-lymphocyte antibodies				Anti-lymphocyte antibodies
		Splenectomy			Splenectomy				Splenectomy
26	53/M	CHOP	Improvement	Lymphoma	CHOP	Improvement	Simultaneous	Lymphoma	CHOP	Improvement	Hypergammaglobulinemia	[23]
26	53/M	Auto	Improvement	Lymphoma	Auto	Improvement	Simultaneous	Lymphoma	Auto	Improvement	Hypergammaglobulinemia	[23]
27	21/F	Cortisone 1.5 mg/kg	Improvement	HA	n.a	Improvement	Simultaneous	HPV B19	Cortisone 1.5 mg/kg	Improvement		[24]
		IVIG		β-thalassemia					IVIG
		CsA							CsA
28	56/F	PSL 50 mg	Improvement	Lymphoma	CHOP	Improvement	Simultaneous	None	PSL 50 mg	Improvement		[25]
29	54/F	CHOP	Improvement	Lymphoma	R-CHOP	Improvement	Simultaneous	Thymoma	CHOP	Improvement		[26]
29	54/F	PSL 1 mg/kg	Improvement	Lymphoma	R-CHOP	Improvement	Simultaneous	Thymoma	PSL 1 mg/kg	Improvement		[26]
30	40/F	mPSL pulse	Improvement	Evan’s syndrome	mPSL pulse	Improvement	6 y	HPV B19	Plasmapheresis	Improvement	Hypogammaglobulinemia	[27]
		AZP 100 mg/day			AZP 100 mg/day				IVIG
		CsA 300 mg/day			CsA 300 mg/day
		Splenectomy			Splenectomy
		Plasmapheresis			Plasmapheresis
31	n.a/n.a	PSL 1 mg/kg	Repeated exacerbations and remissions	Evan’s syndrome	Splenectomy	Improvement	n.a	HPV B19	IVIG	Repeated exacerbations and remissions	Hypogammaglobulinemia	[28]
31	n.a/n.a	Rituxan	Repeated exacerbations and remissions	MPGN	Splenectomy	Improvement	n.a	HPV B19	IVIG	Repeated exacerbations and remissions	Hypogammaglobulinemia	[28]
32	71/F	THP-COP	Improvement	Lymphoma	THP-COP	Improvement	Simultaneous	Lymphoma	THP-COP	Improvement	Polyclonal hypergammaglobulinemia	[29]
32	71/F	PSL 40 mg	Improvement	Lymphoma	THP-COP	Improvement	Simultaneous	Lymphoma	PSL 40 mg	Improvement	Polyclonal hypergammaglobulinemia	[29]
33	54/F	mPSL pulse	Improvement	Lymphoma	R-CHOP	Improvement	Simultaneous	Lymphoma	mPSL pulse	Improvement	Polyclonal hypergammaglobulinemia	[30]
		Plasmapheresis			Auto				Plasmapheresis
		R-CHOP							R-CHOP
		Auto							Auto
34	28/F	Cortisone 15-20 mg	n.a	Retinal detachment	Surgery	Improvement	n.a	HPV B19	Cortisone 15-20 mg	n.a		[31]
34	28/F	IVIG	n.a	Retinal detachment	Surgery	Improvement	n.a	HPV B19	IVIG	n.a		[31]
35	33/F	mPSL pulse	Improvement	Evan’s syndrome	PSL	Improvement	-22 D	HPV B19	PSL	Improvement	Polyclonal hypergammaglobulinemia	[32]
		PSL 60 mg		DM	Insulin				CsA
				Hashimoto’s disease
36	42/F	PSL 40 mg	Improvement	SLE	PSL 40 mg	n.a	Simultaneous	SLE	PSL 40 mg	Improvement		[33]
		mPSL pulse			mPSL pulse				mPSL pulse
		MZB			MZB				MZB
37	26/F	PSL 50 mg	Improvement	None	None	None	3 W	None	PSL 50 mg	Improvement		[34]
37	26/F	PSL 50 mg	Improvement	None	None	None	3 W	None	AZP	Improvement		[34]
38	47/M	PSL 60 mg	Improvement	Congenital chromosomal abnormality/balanced reciprocal translocation	None	None	24 M	HPV B19	PSL 60 mg	Improvement	Hypogammaglobulinemia	The present case
38	47/M	PSL 60 mg	Improvement		None	None	Simultaneous with recurrent AIHA	HPV B19	mPSL pulse	Improvement	Hypogammaglobulinemia	The present case

AIHA autoimmune hemolytic anemia, PRCA pure red cell aplasia, M man, ACTH adenocorticotropic hormone, F female, M month, n.a not available, PSL prednisolone, W week, Tb tubercle bacillus, mPSL methylprednisolone, SLE systemic lupus erythematosus, VCR vincristine sulfate, AZP azathioprine, RA rheumatoid arthritis, COP cyclophosphamide, vincristine, and prednisolone, B-CLL B cell-type chronic lymphocytic leukemia, HPV B19 human parvovirus B19, Y year, CPA cyclophosphamide, HA hepatitis A. IVIG intravenous immunoglobulin, MACOPB methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin, CsA cyclosporine A, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisolone, MPGN membrano proliferative glomerulonephritis, THP-COP pirarubicin vincristine, and prednisolone, Auto autologous peripheral blood stem cell transplantation, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, DM diabetes mellitus, D day, MZB mizoribine.